Cold agglutinin disease is a classical-complement hemolytic anemia distinct from warm AIHA — and primary CAD must be separated from secondary cold agglutinin syndrome.
Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia in which a cold-reactive IgM autoantibody binds red blood cells at low temperatures, agglutinates them, and activates the classical complement pathway through the C1 complex. Complement C3b opsonization drives predominantly extravascular hemolysis in the liver, with a variable intravascular component, producing chronic anemia, profound fatigue, and cold-induced circulatory symptoms (acrocyanosis, Raynaud-like phenomena). Unlike warm autoimmune hemolytic anemia, CAD is mediated by IgM and the classical complement pathway, which is why complement-directed therapy (not corticosteroids) became the rational treatment target.
The clinical and commercial population divides into primary CAD and secondary cold agglutinin syndrome (CAS). Primary CAD is a distinct clonal low-grade lymphoproliferative bone marrow disorder producing the pathogenic monoclonal IgM; CAS is secondary to infection (e.g., Mycoplasma pneumoniae, Epstein–Barr virus), B-cell lymphoma, or other autoimmune disease. US epidemiology is small and now better characterized: a 2016–2023 multi-database claims analysis estimated CAD incidence at 0.6–1.2 per 100,000 person-years and 1-year prevalence at 1.4–3.1 per 100,000, higher in women and rising with age — an order-of-magnitude US prevalent pool around 5,000 patients.
CAD disease characterisation — mechanism, subtypes, and burden
| Dimension | Primary CAD | Cold Agglutinin Syndrome (CAS) |
|---|---|---|
| Underlying cause | Clonal low-grade B-cell lymphoproliferative bone-marrow disorder | Secondary to infection (Mycoplasma, EBV), B-cell lymphoma, or autoimmune disease |
| Autoantibody | Monoclonal cold-reactive IgM | Poly- or monoclonal cold-reactive IgM, cause-dependent |
| Complement mechanism | Classical pathway via C1 → C3b opsonization → extravascular hemolysis | Same classical-pathway hemolysis; often acute/transient with infection |
| Course | Chronic, relapsing; lifelong | Variable; may resolve when trigger clears or track the underlying malignancy |
| Treatment implication | Complement-directed therapy (sutimlimab) and B-cell-directed regimens | Treat underlying cause; supportive care; complement inhibition in severe cases |
Sources: PLoS One 2025 US epidemiology (PMID 40570006); CARDINAL, NEJM 2021 (PMID 33826820); classical-complement pathway and CAD/CAS classification literature.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • US CAD incidence and prevalence from multi-database claims analysis • Age and sex distribution and diagnostic ascertainment • Primary CAD (clonal lymphoproliferative) vs secondary CAS (infection, lymphoma, autoimmune) • Implications of the split for addressable-population sizing
Delivers
- • Cold-reactive IgM binding and classical complement pathway activation via C1 • C3b opsonization, extravascular vs intravascular hemolysis • Contrast with warm AIHA and the rationale for C1s inhibition • Thermal-amplitude and biomarker considerations (LDH, bilirubin, DAT/C3d)
Delivers
- • Anemia severity, transfusion dependence, and fatigue burden • Cold-induced circulatory symptoms and thrombosis considerations • Diagnostic delay and misclassification as other anemias • Residual unmet need after sutimlimab's approval
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Cold-reactive IgM autoantibodies bind red cells and activate the classical complement pathway through C1, with C3b opsonization driving predominantly extravascular hemolysis
- Why CAD's IgM/classical-complement mechanism, unlike warm autoimmune hemolytic anemia, makes complement-directed therapy the rational target instead of corticosteroids
- A 2016–2023 US claims analysis estimated CAD incidence at 0.6–1.2 per 100,000 person-years and 1-year prevalence at 1.4–3.1 per 100,000
- The US prevalent pool is roughly 5,000 patients, skewing female with a median age around 71 in the CARDINAL cohort
- Primary CAD is a distinct clonal low-grade lymphoproliferative bone-marrow disorder producing pathogenic monoclonal IgM, a chronic, relapsing, lifelong condition
- Secondary cold agglutinin syndrome tracks an underlying trigger, Mycoplasma pneumoniae, Epstein-Barr virus, B-cell lymphoma, or autoimmune disease, and may resolve when the trigger clears
- Chronic extravascular hemolysis produces persistent anemia and profound fatigue as the defining symptom burden
- Cold-induced circulatory symptoms, acrocyanosis and Raynaud-like phenomena, compound the anemia and fatigue burden
- Diagnostic delay and misclassification as other anemias remain common before CAD's cold-reactive IgM mechanism is confirmed
- Thermal-amplitude testing alongside LDH, bilirubin and DAT/C3d biomarkers anchors the diagnostic workup that distinguishes CAD from other hemolytic anemias
- Where residual unmet need persists even after sutimlimab's 2022 approval, particularly for patients outside the pivotal-trial populations
- Why a roughly 5,000-patient US pool, split between primary CAD and secondary CAS, keeps addressable-population sizing central to unmet-need assessment
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary sources (peer-reviewed epidemiology and clinical literature, regulatory databases, and registry data), not secondary summaries or unverified estimates. Epidemiological figures are triangulated across sources and carry citations; if a figure cannot be sourced to a live record, it does not ship.
US Cold Agglutinin Disease Landscape sources: peer-reviewed epidemiology (PLoS One 2025 multi-database US claims analysis, PMID 40570006), primary clinical literature on complement-mediated hemolysis and CAD biology, the CARDINAL and CADENZA trial publications, and standard hematology references distinguishing primary CAD from secondary cold agglutinin syndrome.
- US CAD incidence and prevalence verified against PLoS One 2025 (PMID 40570006)
- Classical-complement hemolysis mechanism verified against CARDINAL trial rationale, NEJM 2021 (PMID 33826820)
- Median age and female predominance verified against Blood Adv 2023 CARDINAL follow-up (PMID 37459203)
- Primary CAD vs cold agglutinin syndrome distinction verified against peer-reviewed hematology literature
Frequently asked questions
Commission this assessment
AXLRx US Cold Agglutinin Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US CAD patient population. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.